Polarean Imaging plc (AIM: POLX), the medical?imaging technology company, with a proprietary drug?device combination product for the magnetic resonance imaging (MRI) market, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP (“SP Angel”) and Northland Capital Partners Ltd, it has appointed SP Angel as its Nominated Adviser and Broker with immediate effect.
Polarean Imaging plc (AIM: POLX), the medical?imaging technology company, with a proprietary drug?device combination product for the magnetic resonance imaging (MRI) market, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP (“SP Angel”) and Northland Capital Partners Ltd, it has appointed SP Angel as its Nominated Adviser and Broker with immediate effect.
AIM Rule 17 Notice
Richard Hullihen, the Company’s Chief Executive Officer, was previously a Director of M2M Imaging Australia Pty Ltd (“M2M Australia”). M2M Australia was placed in voluntary administration in 2013 while Richard Hullihen was on the board. M2M Australia was subsequently liquidated and dissolved in 2015.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Enquiries:
| Polarean Imaging plc |
| Richard Hullihen, Chief Executive Officer |
| Via Walbrook PR |
| Richard Morgan, Chairman |
| SP Angel Corporate Finance LLP |
| Tel: +44 (0)20 3470 0470 |
| David Hignell |
|
|
| Lindsay Mair |
|
|
|
|
| MC Services (European IR) |
| Tel: +49 (0)89 210 2280 |
| Raimund Gabriel |
|
|
|
|
| Walbrook PR |
| Paul McManus / Anna Dunphy |
| Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
